Discover the X Factor in Wound Care

BlastX is a breakthrough antimicrobial wound gel powered by Next Science’s patented, non-toxic, biofilm-disruption Xbio technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment.29

Others only address the tip of the iceberg.

BlastX goes deeper to help solve the
problem of bacterial biofilm:


the bacterial biofilm matrix

As opposed to free-floating bacteria, biofilms are powerful communities that function as a single entity with robust defense mechanisms. By targeting the biofilm structure and breaking it apart, Next Science's Xbio technology deconstructs the biofilm matrix without harming healthy human tissue.*


bacteria within the technology

With the biofilm matrix dissolved, bacteria are exposed and more vulnerable to attack. The Xbio technology creates a high osmolarity condition. This environment coupled with a surfactant induces cell lysis for bacteria enveloped within the gel. Cell lysis is nondiscriminatory, therefore Xbio destroys gram-positive and gram-negative bacteria, persister cells and spores. *


from recolonization

Disrupting and destroying the biofilm matrix can reduce the rate of recurrence more than 100x, effectively defending against recolonization. Other antimicrobial agents may claim to destroy biofilms; however their efficacy could be undermined by bacterial resistance. In contrast, the biofilm matrix cannot re-form in the presence of the BlastX wound gel. There is no known evidence of bacterial resistance to the Xbio technology. *


* Laboratory testing on file

Mayo Clinic Study Reveals BlastX™ Significantly Improves Wound Area Reduction and Closure*

A 12-week, randomized, open-label clinical trial at Mayo Clinic Jacksonville, FL, demonstrated the healing power of BlastX.

‣‣Wound Area Reduction:

69% (more than 2.4x) greater area reduction  for BlastX vs. 29% for control (P < 0.001)

Average wound size – 11cm2; Average wound duration – 21 months; Average pt. Age – 61

* Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach

‣‣Wound Closure: 213%* relative increase in healing versus control (52% BlastX vs. 17% control)

Clinical and Scientific Studies on Biofilm Disruption and BlastX™

For additional clinical and scientific studies about biofilms and BlastX’s performance, download the following publications:

Randomized Control Trail Determines BlastX Biofilm-Disruption Therapeutically Efficacious in Chronic Wounds

Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim A. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach. Wounds. Epub 2018.

Pivotal Randomized Control Trial Demonstrates BlastX improved Wound Healing

Wolcott R. Disrupting the biofilm matrix improves wound healing outcomes. Journal of wound care. 2015 Aug;24(8):366-71.

U.S. Consensus Paper focuses on the Importance of Biofilm Disruption in Treating Chronic Wounds and calls out the promise of high osmolarity surfactant technology

Snyder RJ, Bohn G, Hanft J, Harkless L, Kim P, Lavery L, Schultz G, Wolcott R. Wound Biofilm: Current Perspectives and Strategies on Biofilm Disruption and Treatments. Wounds: a compendium of clinical research and practice. 2017 Jun;29(6):S1-S17.

Additional Published Biofilm Education


Elevate Your Standard of Care with Effective Antibiofilm Technology

This peer-reviewed paper supports the need for a paradigm shift toward biofilm disruption strategies for wound healing.

‣‣Upgrade your standard of care: Follow this recommended step-down/step-up approach with the use of biofilm-disruption technology for the treatment of wounds.

Independent testing conducted at the Montana State University Center for Biofilm Engineering
BlastX™ Supersedes Current Therapy by Reducing Biofilm Bacteria 4-6 Log in Laboratory Tests24,41

In in vitro studies, BlastX was compared to multiple current topical antimicrobial therapies. 24 hours after application, measurements were taken for two different kinds of biofilm bacteria (S. aureus and P. aeruginosa).


BlastX is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial- and full-thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second degree burns, and grafted and donor sites.


BlastX is non-toxic and compatible with a broad range of advanced healing modalities that set the stage for better preparation and ongoing care of the wound bed.

Global Access

BlastX Antimicrobial Wound Gel is distributed worldwide exclusively by 3M.

MPN-WEB-003 Rev B